2nd Subcommittee on children's medicines (2008): Applications for:
Additional formulations:
- Chlorhexidine (New formulation)
- Lamivudine, nevirapine, zidovudine (New formulation)
- Lamivudine, stavudine, nevirapine (New formulation)
- Lamivudine, zidovudine (New formulation)
Additional medicines:
- Cefalexin (Inclusion)
- Hydrocortisone and fludrocortisone (Inclusion)
- Liposomal amphotericin B (Inclusion)
- Medicines used in palliative care (Inclusion)
- Pancreatic enzymes (Inclusion)
- Pralidoxime (Inclusion)
- Surfactant (Inclusion)
Deletion of a formulation:
Review:
- Acetylcysteine (Review)
- Antiemetic medicines (Review)
- Carbapenems (Review)
- Ceftazidime (Review)
- Ceftriaxone (Review)
- Charcoal, activated (Review)
- Cytotoxic medicines (Review)
- Dermatological medicines (Review)
- Fluoroquinolones (Review)
- Gentamicin (Review)
- Macrolides (Review)
- Methotrexate (Review)
- Procaine benzylpenicillin (Review)
- Psychotherapeutic medicines (Review)
- Quinidine (Review)
- Rheumatic Fever and Rheumatic Heart Disease (Review)
- Salbutamol (Review)
- Sulfadiazine (Review)
- TB medicines (Review)
- Tetracycline (Review)
New section:
Contact: emlsecretariat@who.int
Medicine Access and Rational Use (MAR)
20 Avenue Appia
CH-1211 Geneva 27